WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade

WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade

Background and purpose: Angiogenesis and lymphangiogenesis are major routes for metastatic spread of tumor cells. It thus represent the rational targets for therapeutic intervention of cancer. Recently, we showed that a novel aliphatic hydroxamate-based compound, WMJ-S-001, exhibits anti-angiogenic,...

Full description

Bibliographic Details
Main Authors: Shiu-Wen Huang, Hung-Yu Yang, Wei-Jan Huang, Wei-Chuan Chen, Meng-Chieh Yu, Shih-Wei Wang, Ya-Fen Hsu, Ming-Jen Hsu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
hydroxamate
lymphangiogenesis
lymphatic endothelial cells (LECs)
p53
p38
survivin
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01188/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01188/full

Similar Items